🇺🇸 FDA
Pipeline program

AZD0292

D7700C00003

Phase 2 mab active

Quick answer

AZD0292 for Bronchiectasis With Pseudomonas Aeruginosa Colonization is a Phase 2 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Bronchiectasis With Pseudomonas Aeruginosa Colonization
Phase
Phase 2
Modality
mab
Status
active

Clinical trials